Jacqueline Reid, NP
Family · Cartersville, GANPI 1033798756
Payments from drug & device makers
Across 223 payments — averaging $22.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- Boehringer Ingelheim$1K
- United Therapeutics Corporation$319
- Sanofi$298
- Mallinckrodt Hospital Products Inc.$295
- AstraZeneca$250
- plus $2K from 25 others
What the payments were for
- Food & beverage$5,036100%
- Education$160%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 47 | $1,086 |
| Boehringer Ingelheim | 49 | $1,069 |
| United Therapeutics Corporation | 9 | $319 |
| Sanofi | 12 | $298 |
| Mallinckrodt Hospital Products Inc. | 13 | $295 |
| AstraZeneca(2 entities) | 15 | $250 |
| Grifols USA, LLC | 10 | $210 |
| Mylan Specialty L.p. | 10 | $199 |
| Amgen | 8 | $165 |
| Regeneron Healthcare Solutions, Inc. | 5 | $155 |
| Merck | 7 | $151 |
| Chiesi USA, Inc. | 1 | $132 |
| Resmed Corp | 6 | $92 |
| Verona Pharma, Inc. | 4 | $84 |
| Actelion Pharmaceuticals US, Inc. | 3 | $65 |
| Harmony Biosciences LLC | 2 | $63 |
| Teva Pharmaceuticals USA, Inc. | 3 | $48 |
| AbbVie | 3 | $41 |
| Insmed, Inc. | 2 | $39 |
| ANI Pharmaceuticals, Inc. | 2 | $38 |
| Pfizer | 2 | $37 |
| Viatris Specialty LLC | 1 | $35 |
| Idorsia Pharmaceuticals US Inc | 1 | $25 |
| Vifor Pharma, Inc. | 1 | $24 |
| Covis Pharma GmbH | 1 | $24 |
| Fisher & Paykel Healthcare Inc | 1 | $21 |
| Baxter Healthcare | 1 | $21 |
| Olympus America Inc. | 1 | $18 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Pulmonx Corporation | 1 | $16 |
| Sandoz | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,052 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 150 | $130,609 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 63 | $49,021 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 57 | $30,771 |
| Spiriva RespimatTiotropium Bromide | 36 | $27,037 |
| Breo ElliptaFluticasone/Vilanterol | 35 | $17,189 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $11,996 |
| Spiriva HandihalerTiotropium Bromide | 18 | $11,227 |
| Advair HfaFluticasone Propion/Salmeterol | 28 | $9,644 |
| Arnuity ElliptaFluticasone Furoate | 18 | $8,890 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 234 | $8,015 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $7,975 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $4,847 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 23 | $4,839 |
| Roflumilast | 16 | $4,047 |
| Wixela InhubFluticasone Propion/Salmeterol | 20 | $2,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $1,086 | $192,306275 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $250 | $56,99692 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $1,069 | $39,03354 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.
Other family in Cartersville
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.